Fucoidan from Fucus vesiculosus Inhibits Inflammatory Response, Both In Vitro and In Vivo

last updated: 2023-09-28
ProjectATLANTIDA :: publications list
TitleFucoidan from Fucus vesiculosus Inhibits Inflammatory Response, Both In Vitro and In Vivo
Publication TypePapers in Scientific Journals
Year of Publication2023
AuthorsWang L., Oliveira C., Li Q., Ferreira A. S., Nunes C., Coimbra M. A., Reis R. L., Martins A., Wang C., Silva T. H., and Feng X.

Fucoidan has been reported to present diverse bioactivities, but each extract has specific features from which a particular biological activity, such as immunomodulation, must be confirmed. In this study a commercially available pharmaceutical-grade fucoidan extracted from Fucus vesiculosus, FE, was characterized and its anti-inflammatory potential was investigated. Fucose was the main monosaccharide (90 mol%) present in the studied FE, followed by uronic acids, galactose, and xylose that were present at similar values (3.8–2.4 mol%). FE showed a molecular weight of 70 kDa and a sulfate content of around 10%. The expression of cytokines by mouse bone-marrow-derived macrophages (BMDMs) revealed that the addition of FE upregulated the expression of CD206 and IL-10 by about 28 and 22 fold, respectively, in respect to control. This was corroborated in a stimulated pro-inflammatory situation, with the higher expression (60 fold) of iNOS being almost completely reversed by the addition of FE. FE was also capable of reverse LPS-caused inflammation in an in vivo mouse model, including by reducing macrophage activation by LPS from 41% of positive CD11C to 9% upon fucoidan injection. Taken together, the potential of FE as an anti-inflammatory agent was validated, both in vitro and in vivo.

JournalMarine Drugs
Date Published2023-05-17
KeywordsAnti-inflammatory, Fucoidan, Fucus vesiculosus, macrophage
Peer reviewedyes

Back to top